gadoxetic acid disodium profile

gadolinium ethoxybenzyl DTPA: DTPA covalently linked to the lipoohilic ethoxybenzyl moiety; a contrast agent in MR imaging of hepatobiliary system [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	91754427
MeSH ID	M0198898

Synonym
gadolinium ethoxybenzyl dtpa
gadoxetate disodium
gd-(s)-eob-dtpa
gadoxetate disodium [usan]
BCP09445
gadoxetatedisodium
CS-0006192
HY-16219
DTXSID001027879

Excerpt	Reference	Relevance
"Gd-EOB-DTPA is safe and efficient for MR imaging of the liver."	( Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Bollow, M; Frenzel, T; Hamm, B; Lange, L; Mühler, A; Staks, T; Taupitz, M; Weinmann, HJ; Wolf, KJ, 1995)	0.29
" Changes in liver signal intensity, lesion-liver contrast-to-noise ration (C/N), detectable liver lesions, side effects, and adverse events were evaluated."	( Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Balzer, T; Berns, T; Daldrup, HE; Hesse, T; Peters, PE; Reimer, P; Rummeny, EJ; Shamsi, K; Tombach, B, 1996)	0.29
"Gd-EOB-DTPA is an efficient, diagnostically useful, and safe contrast agent."	( Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Balzer, T; Berns, T; Daldrup, HE; Hesse, T; Peters, PE; Reimer, P; Rummeny, EJ; Shamsi, K; Tombach, B, 1996)	0.29
" Adverse events were recorded, and patient monitoring and laboratory assay were performed at time of injection and up to 24 hours after contrast material administration."	( Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Amendola, M; Balzer, T; Bluemke, DA; Breuer, J; Brown, JJ; Casalino, DD; Davis, PL; Francis, IR; Krinsky, G; Lee, FT; Lu, D; Paulson, EK; Sahani, D; Schwartz, LH; Shamsi, K; Siegelman, ES; Small, WC; Weber, TM; Welber, A, 2005)	0.33
"Compared with precontrast MR imaging, postcontrast MR imaging with Gd-EOB-DTPA demonstrated improved sensitivity for lesion detection in the majority of blinded readers, with no substantial adverse events."	( Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Amendola, M; Balzer, T; Bluemke, DA; Breuer, J; Brown, JJ; Casalino, DD; Davis, PL; Francis, IR; Krinsky, G; Lee, FT; Lu, D; Paulson, EK; Sahani, D; Schwartz, LH; Shamsi, K; Siegelman, ES; Small, WC; Weber, TM; Welber, A, 2005)	0.33
" No serious adverse events occurred."	( Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials. Gokan, T; Hirohashi, S; Kadoya, M; Kawamura, Y; Kuwatsuru, R; Tanimoto, A, 2006)	0.33
" The no observed adverse effect levels after repeated administration markedly exceeds the single diagnostic dose in humans and no unexpected organ toxicity was observed."	( Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Döhr, O; Hofmeister, R; Schweinfurth, H; Treher, M, 2007)	0.34
"Gd-EOB-DTPA was well tolerated with high safety margins between the single diagnostic dose and the doses showing adverse effects in animal studies."	( Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Döhr, O; Hofmeister, R; Schweinfurth, H; Treher, M, 2007)	0.34
" Adverse events (AEs) were recorded and evaluated with regard to a potential drug relationship."	( Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance. Balzer, T; Breuer, JA; Dohanish, S; Endrikat, JS, 2015)	0.42
" The number of patients, the characteristics of adverse events, related adverse events, and serious adverse events were analyzed."	( Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients. Breuer, J; Dohanish, S; Endrikat, J; Kim, SY; Sakaguchi, T, 2016)	0.43
" A comparison between elderly (≥65 years) versus adults (18-64 years) was performed with respect to the frequency of drug-related adverse events (AEs) in clinical phase II-III studies and adverse drug reactions (ADRs) in the pharmacovigilance database."	( Safety profile of gadoxetate disodium in elderly patients (≥65 years). Breuer, J; Dohannish, S; Endrikat, J; Schwenke, C; Vogtlaender, K, 2018)	0.48
" Purpose To perform a systematic review and meta-analysis of gadoxetic acid adverse events, including immediate hypersensitivity reactions, NSF, and intracranial gadolinium retention."	( Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis. Davenport, MS; Maralani, PJ; Schieda, N; Tsampalieros, AK; van der Pol, CB; Walker, D; Woo, S, 2020)	0.56

Excerpt	Reference	Relevance
" Results of laboratory tests, clinical measurements, and pharmacokinetic data were obtained in 44 healthy volunteers in a double-blind, randomized, placebo-controlled design."	( Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Bollow, M; Frenzel, T; Hamm, B; Lange, L; Mühler, A; Staks, T; Taupitz, M; Weinmann, HJ; Wolf, KJ, 1995)	0.29
" The pharmacokinetic behaviour in rats, dogs and monkeys could be well described by disposition of the compound in the central and peripheral compartment with elimination occurring from the central compartment, allowing for Michaelis-Menten kinetics for the extrarenal (biliary) route of elimination and linear kinetics for the renal route of elimination."	( Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Schuhmann-Giampieri, G, 1993)	0.29
" Pharmacokinetic behavior was compared with the compute tomographic attenuation data in the liver parenchyma after the same doses in patients."	( Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. Mahler, M; Maibauer, R; Röll, G; Schmitz, S; Schuhmann-Giampieri, G, 1997)	0.3
"To compare the value of enhancement and pharmacokinetic parameters measured at dynamic gadoxetate-enhanced magnetic resonance (MR) imaging in determining hepatic organic anion transporter expression in control rats and rats with advanced liver fibrosis."	( Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Daire, JL; Doblas, S; Fasseu, M; Giraudeau, C; Lagadec, M; Lambert, SA; Moreau, R; Paradis, V; Pastor, CM; Ronot, M; Van Beers, BE; Vilgrain, V, 2015)	0.42
" Enhancement parameters (maximum enhancement [Emax], time to peak [Tmax], and elimination half-life) were measured on enhancement-versus-time curves, and pharmacokinetic parameters (hepatic extraction fraction [HEF] and mean residence time [MRT]) were obtained by means of deconvolution analysis of the concentration-versus-time curves in the liver and the portal vein."	( Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Daire, JL; Doblas, S; Fasseu, M; Giraudeau, C; Lagadec, M; Lambert, SA; Moreau, R; Paradis, V; Pastor, CM; Ronot, M; Van Beers, BE; Vilgrain, V, 2015)	0.42
"In rats with advanced liver fibrosis, the Emax, Tmax, HEF, and MRT decreased significantly relative to those in control rats, whereas the elimination half-life increased significantly."	( Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Daire, JL; Doblas, S; Fasseu, M; Giraudeau, C; Lagadec, M; Lambert, SA; Moreau, R; Paradis, V; Pastor, CM; Ronot, M; Van Beers, BE; Vilgrain, V, 2015)	0.42
"The pharmacokinetic parameter HEF at dynamic gadoxetate-enhanced MR imaging is independently correlated with hepatic organic anion transporter expression."	( Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Daire, JL; Doblas, S; Fasseu, M; Giraudeau, C; Lagadec, M; Lambert, SA; Moreau, R; Paradis, V; Pastor, CM; Ronot, M; Van Beers, BE; Vilgrain, V, 2015)	0.42
"To determine whether pharmacokinetic modeling parameters with different output assumptions of dynamic contrast-enhanced MRI (DCE-MRI) using Gd-EOB-DTPA correlate with serum-based liver function tests, and compare the goodness of fit of the different output assumptions."	( Hepatic function imaging using dynamic Gd-EOB-DTPA enhanced MRI and pharmacokinetic modeling. Chen, H; Ning, J; Sun, Y; Xie, S; Yang, Z; Yuan, C, 2017)	0.46
"To determine whether the pharmacokinetic parameters of Gd-EOB-DTPA can identify the difference in liver function in a rat hepatectomy model."	( Assessment of Liver Function Using Pharmacokinetic Parameters of Gd-EOB-DTPA: Experimental Study in Rat Hepatectomy Model. Byun, JH; Hwang, DW; Kim, HJ; Kim, KW; Kim, SY; Lee, YJ; Lim, HS; You, MW, 2018)	0.48
" However, accurate pharmacokinetic modeling in the liver is challenging since it has two vascular inputs and it is subject to large deformation and displacement due to respiration."	( A pharmacokinetic model including arrival time for two inputs and compensating for varying applied flip-angle in dynamic gadoxetic acid-enhanced MR imaging. Cieslak, KP; Lavini, C; Runge, JH; Stoker, J; van Gulik, T; van Vliet, LJ; Vos, FM; Zhang, T, 2019)	0.51
"Our work primarily targeted to improve pharmacokinetic modeling for DCE-MRI of the liver."	( A pharmacokinetic model including arrival time for two inputs and compensating for varying applied flip-angle in dynamic gadoxetic acid-enhanced MR imaging. Cieslak, KP; Lavini, C; Runge, JH; Stoker, J; van Gulik, T; van Vliet, LJ; Vos, FM; Zhang, T, 2019)	0.51
" Pharmacokinetic parameters were compared between the two isomers and between Child-Pugh classifications using student's t test."	( Dual Plasma Sampling Method to Determine the Hepatic and Renal Clearance of the 2 Diastereoisomers of Gd-EOB-DTPA. Ao, G; Cai, Y; Chen, M; Chen, Y; Peng, Y; Shi, W; Wang, S; Yuan, X, 2020)	0.56
" Using a minimal physiological-based pharmacokinetic (PBPK) model, it has been shown for the first time, that the rapid initial decline of plasma concentration after intravenous injection is the result of an uptake into hepatocytes rather than of a distribution into the extravascular extracellular space."	( Unusual Distribution Kinetics of Gadoxetate in Healthy Human Subjects Genotyped for OATP1B1: Application of Population Analysis and a Minimal Physiological-Based Pharmacokinetic Model. Siegmund, W; Weiss, M, 2021)	0.62
"Physiologically based pharmacokinetic (PBPK) models are increasingly used in drug development to simulate changes in both systemic and tissue exposures that arise as a result of changes in enzyme and/or transporter activity."	( Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. Darwich, AS; Galetin, A; Melillo, N; Ogungbenro, K; Schütz, G; Scotcher, D; Sourbron, S; Tadimalla, S; Ziemian, S, 2021)	0.62

Excerpt	Reference	Relevance
"To investigate whether the malignancy of atypical nodules in cirrhosis can be identified at gadoxetic-acid-disodium(Gd-EOB-DTPA)-MRI by their hypointensity in the hepatobiliary(HB)-phase alone or combined with any other MR imaging features."	( Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. Corcioni, B; Dettori, E; Dormi, A; Golfieri, R; Grazioli, L; Lucidi, V; Orlando, E; Renzulli, M; Romanini, L, 2012)	0.38
" Per-nodule sensitivity, specificity, negative and positive predictive values (NPV/PPV), and diagnostic accuracy were calculated for HB-phase hypointensity alone, and combined with vascular patterns and T2w hyperintensity."	( Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. Corcioni, B; Dettori, E; Dormi, A; Golfieri, R; Grazioli, L; Lucidi, V; Orlando, E; Renzulli, M; Romanini, L, 2012)	0.38
"Gadoxetic acid-enhanced magnetic resonance imaging (MRI) in combination with diffusion-weighted MRI (Gd-EOB-MRI/DWI) has become popular for evaluating colorectal liver metastases (CRLM)."	( Feasibility of Routine Application of Gadoxetic Acid-Enhanced MRI in Combination with Diffusion-Weighted MRI for the Preoperative Evaluation of Colorectal Liver Metastases. Esaki, M; Hiraoka, N; Kishi, Y; Miyake, M; Nagino, M; Nara, S; Shimada, K; Tanaka, M, 2016)	0.43
" This paper aims to evaluate the use of Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging combined with T1 mapping for the diagnosis of HCC and assessing its degree of differentiation."	( Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma. Cai, H; Chan, T; Dong, Z; Feng, ST; Jiang, M; Li, ZP; Luo, Y; Peng, Z, 2016)	0.43
" The efficacy of the proposed technique was assessed for its ability to provide quantitative insights into drug-drug interactions (DDIs), using rifampicin as inhibitor."	( Modeling Gadoxetate Liver Uptake and Efflux Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Enables Preclinical Quantification of Transporter Drug-Drug Interactions. Blé, FX; Georgiou, L; Hubbard Cristinacce, PL; Naish, JH; Nicholls, G; Penny, J; Woodhouse, N, 2018)	0.48

Excerpt	Reference	Relevance
" In the Mrp2-deficient rats, oral bioavailability increased to approximately 21% and Gd-EOB-DTPA was exclusively excreted into urine."	( Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Hosten, N; Jedlitschky, G; Jia, J; Keiser, M; Kühn, JP; Oswald, S; Puls, D; Siegmund, W; Weitschies, W, 2014)	0.4
" The logarithms of the absorption rate constants (logKa values) and of the elimination rate constants (logKe values) were calculated for each experimental condition, and between-group differences were compared using Student's t-test."	( The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. Abe, O; Akai, H; Inoue, Y; Kiryu, S; Kunimatsu, A; Nojima, M; Ohtomo, K; Yasaka, K, 2018)	0.48

Excerpt	Relevance	Reference
" The dosage for hyperintense visualization of intrahepatic bile ducts is 10 micromol/kg."	( Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Bollow, M; Hamm, B; Staks, T; Taupitz, M; Weinmann, HJ; Wolf, KJ, 1997)	0.3
"At the dosage used in this study, Gd-BOPTA yields higher maximum enhancement of the hepatic artery, portal vein, and middle hepatic vein during the arterial and the portal venous phase and during the delayed phases than Gd-EOB-DTPA does, whereas there is no difference in liver parenchymal enhancement between the two contrast agents."	( Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Albiin, N; Brismar, TB; Dahlstrom, N; Edsborg, N; Persson, A; Smedby, O, 2009)	0.35
" MR imaging was performed before dosing and at preset times after dose administration to determine enhancement relative to predose signal intensity values."	( Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Breuer, J; Ebert, W; Gschwend, S; Schultze-Mosgau, M, 2011)	0.37
" After the oral administration to the wild-type animals, Gd-EOB-DTPA was considerably absorbed from the small intestine (bioavailability, approximately 17%) and predominately eliminated via feces after intravenous dosing (approximately 96%)."	( Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Hosten, N; Jedlitschky, G; Jia, J; Keiser, M; Kühn, JP; Oswald, S; Puls, D; Siegmund, W; Weitschies, W, 2014)	0.4
" The aim of this study was to determine the optimal dosage of Gd-EOB-DTPA for contrast-enhanced magnetic resonance cholangiography (ce-MRC) with reference to contrast-enhanced CT cholangiography (ce-CTC)."	( Bile duct evaluation of potential living liver donors with Gd-EOB-DTPA enhanced MR cholangiography: Single-dose, double dose or half-dose contrast enhanced imaging. Forsting, M; Kinner, S; Maderwald, S; Radtke, A; Schroeder, T; Sotiropoulos, G; Steinweg, V, 2014)	0.4
"Ce-MRC is at any dosage inferior to ce-CTC."	( Bile duct evaluation of potential living liver donors with Gd-EOB-DTPA enhanced MR cholangiography: Single-dose, double dose or half-dose contrast enhanced imaging. Forsting, M; Kinner, S; Maderwald, S; Radtke, A; Schroeder, T; Sotiropoulos, G; Steinweg, V, 2014)	0.4
"To determine if amiodarone induces hepatic phospholipidosis (PLD) sufficient to detect changes in hepatobiliary transporter function as assessed by gadoxetate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), rats were orally dosed with vehicle (1% methyl cellulose) or amiodarone (300 mg/kg/day) for 7 consecutive days."	( Hepatic Phospholipidosis Is Associated with Altered Hepatobiliary Function as Assessed by Gadoxetate Dynamic Contrast-enhanced Magnetic Resonance Imaging. Goulbourne, CN; Jucker, BM; Lenhard, SC; Lev, M; Miller, RT; Peterson, RA; Webster, LO, 2016)	0.43
" Plasma trough concentrations, and concentrations at 2, 4, and 6 h after dosing were determined 7 d after the start of treatment."	( Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. Ando, H; Fukada, H; Ikejima, K; Miyazaki, A; Morishige, J; Nakadera, E; Okubo, H; Sorin, Y, 2018)	0.48
" Finally, we illustrated how such a framework could be useful for drug dosage selection, and how it potentially can be applied in personalized treatments designed to avoid DILI."	( Mathematical models for biomarker calculation of drug-induced liver injury in humans and experimental models based on gadoxetate enhanced magnetic resonance imaging. Cedersund, G; Dahlström, N; Karlsson, M; Lundberg, P; Simonsson, C, 2023)	0.91
" A logistic dose-response model was used to estimate the fraction of liver functional loss, and NTCP was estimated using the cumulative functional reserve model for changes in Child-Pugh (C-P) scores."	( Deep learning prediction of post-SBRT liver function changes and NTCP modeling in hepatocellular carcinoma based on DGAE-MRI. Aryal, MP; Cao, Y; Cuneo, K; Lawrence, TS; Matuszak, M; Naqa, IE; Ten Haken, RK; Wei, L, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	45 (2.82)	18.2507
2000's	71 (4.45)	29.6817
2010's	1096 (68.63)	24.3611
2020's	385 (24.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	95 (5.52%)	5.53%
Reviews	134 (7.79%)	6.00%
Case Studies	83 (4.83%)	4.05%
Observational	26 (1.51%)	0.25%
Other	1,382 (80.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
glycine [no description available]	2.11	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..	2.84	3	0	diatomic iodine	nutrient
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.05	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
pyridoxal phosphate Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.	6.96	9	1	methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 phosphate	coenzyme; cofactor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.13	1	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	10.04	37	7	pentacarboxylic acid	copper chelator
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.08	4	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
iodixanol iodixanol: dimeric contrast media; structure given in first source. iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.	3.06	1	0	organoiodine compound	radioopaque medium
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	3.55	8	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iomeprol iomeprol: structure given in first source. iomeprol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.	4.97	2	1	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.	3.43	7	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	3.06	1	0	organic molecular entity
ioversol [no description available]	2.06	1	0	amidobenzoic acid
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	2.06	1	0	organofluorine compound	inhalation anaesthetic
sulfobromophthalein Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.	2.7	3	0	2-benzofurans; organobromine compound; organosulfonic acid; phenols	dye
methacetin methacetin: RN given refers to parent cpd. methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group.	3.11	4	0	acetamides; aromatic ether
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	3.39	6	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
n-nitrosomorpholine N-nitrosomorpholine : A nitrosamine that is morpholine in which the hydrogen attached to the nitrogen is replaced by a nitroso group. A carcinogen and mutagen, it is found in snuff tobacco.	2.06	1	0	nitrosamine	carcinogenic agent; mutagen
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	6.96	9	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.41	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.7	3	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.41	1	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
diethylenetriamine diethylenetriamine: RN given refers to parent cpd	2.41	1	0	polyazaalkane; triamine
meglumine Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.	18.46	80	3	hexosamine; secondary amino compound
iminodiacetic acid iminodiacetic acid: used as hepatobiliary imaging agent when labeled with Tc; RN given refers to parent cpd; structure. iminodiacetic acid : An amino dicarboxylic acid that is glycine in which one of the hydrogens attached to the nitrogen is substituted by a carboxymethyl group.	2.13	1	0	amino dicarboxylic acid; glycine derivative; non-proteinogenic alpha-amino acid	chelator
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.08	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
perfluorobutane perfluorobutane: component of the echo contrast agent, BR14, which consists of perfluorobutane gas microbubbles. perflubutane : A fluorocarbon that is butane in which all of the hydrogens have been replaced by fluorines. Microbubbles of preflubutane are used in the ultrasound contrast agent BR14.	8.43	22	2	fluoroalkane; fluorocarbon; gas molecular entity	ultrasound contrast agent
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	3.45	1	1	cyclic ketone; erythromycin
sulfur hexafluoride Sulfur Hexafluoride: Sulfur hexafluoride. An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber and as a tracer in monitoring the dispersion and deposition of air pollutants.. sulfur hexafluoride : A sulfur coordination entity consisting of six fluorine atoms attached to a central sulfur atom. It is the most potent greenhouse gas currently known, with a global warming potential of 23,900 times that of CO2 over a 100 year period (SF6 has an estimated lifetime in the atmosphere of between 800 and 3,000 years).	2.77	3	0	sulfur coordination entity	greenhouse gas; NMR chemical shift reference compound; ultrasound contrast agent
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	3.82	3	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	18.04	63	7	f-block element atom; lanthanoid atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.1	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	1.99	1	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	1.98	1	0	benzenes; phenyl acetates
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	2.11	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
ioxitalamic acid ioxitalamic acid: RN given refers to parent cpd; Telebrix 38 contains both sodium ioxitalamate & meglumine ioxitalamate; structure. iooxitalamic acid : An organoiodine compound that is 2,4,6-triiodobenzoic acid substituted by an acetylamino group at position 3 and a (2-hydroxyethyl)carbamoyl group at position 5. It is used as a contrast medium.	3.06	1	0	acetamides; benzoic acids; dicarboxylic acid monoamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
mebrofenin [no description available]	2.41	1	0	amino acid amide
irinotecan [no description available]	2.1	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
gadolinium chloride gadolinium chloride: a macrophage inhibitor; reduces pulmonary injury and inflammatory mediator production induced by inhaled ozone	1.98	1	0	gadolinium coordination entity	TRP channel blocker
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	5.27	3	1	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
iridium radioisotopes Iridium Radioisotopes: Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.	2.47	2	0
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	5.28	18	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
yttrium radioisotopes Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.	2.8	3	0
gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate: RN refers to Na salt	3.37	5	0
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.66	2	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
edotreotide Edotreotide: DOTA - 1,4,7,10-tetraazacyclododecanetetracetic acid; structure given in first source; may be labelled with various radioisotopes	3.46	1	1
technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.	3.24	5	0
lapatinib [no description available]	2.08	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	4.23	3	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
thioacetamide Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.	3.18	5	0	thiocarboxamide	hepatotoxic agent
2-fluoro-2-deoxyglucose-6-phosphate 2-fluoro-2-deoxyglucose-6-phosphate: metabolite of 2-fluoro-2-deoxyglucose; RN given refers to D-Glu cpd; RN for parent cpd not avail 10/90	3.51	1	1
bilirubin [no description available]	5.89	20	1	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.1	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	1.99	1	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	24.07	1,565	86	gadolinium coordination entity	MRI contrast agent
phosphocreatine Phosphocreatine: An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996). phosphagen : Any of a group of guanidine or amidine phosphates that function as storage depots for high-energy phosphate in muscle with the purpose of regenerating ATP from ADP during muscular contraction.. N-phosphocreatine : A phosphoamino acid consisting of creatine having a phospho group attached at the primary nitrogen of the guanidino group.	1.98	1	0	phosphagen; phosphoamino acid	human metabolite; mouse metabolite
technetium tc 99m mebrofenin technetium Tc 99m mebrofenin: hepatobiliary radiopharmaceutical	2.11	1	0
sepharose agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.	1.99	1	0
indocyanine green Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.	4.32	16	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
rifamycins [no description available]	2	1	0
optimark [no description available]	5.84	3	0
gadofosveset trisodium gadofosveset trisodium: a low molecular weight molecule chelated to Gadolinium, that strongly binds to plasma proteins; Vasovist is an injectable for imaging the vascular system by magnetic resonance angiography	7.15	10	0
abt-450 paritaprevir: inhibits HCV NS3 protease. paritaprevir : An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.17	1	0
n,n'-bis(pyridoxal-5-phosphate)ethylenediamine-n,n'-diacetic acid [no description available]	6.96	9	1
transforming growth factor alpha Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.	2.07	1	0
gallium ga 68 dotatate gallium Ga 68 dotatate: A radioactive diagnostic agent used for POSITRON EMISSION TOMOGRAPHY (PET) imaging of SOMATOSTATIN RECEPTOR positive neuroendocrine tumors and malignant abdominal paraganglioma.	2.1	1	0
68ga-dotanoc 68Ga-DOTANOC: a PET imaging compound specific to somatostatin receptors subtypes 2 and 5; no further info available 10/2005	2.08	1	0
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	3.63	2	0	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.52	2	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.07	1	0

Condition	Relationship Strength	Studies	Trials
Margins of Excision The edges of tissue removed in a surgery for assessment of the effectiveness of a surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. When the margin is negative or not involved by tumor (e.g., CANCER) it suggests all of the tumor has been removed by the surgery.	3.33	1	0
Hepatocellular Carcinoma [description not available]	19.81	650	28
Cancer of Liver [description not available]	22.06	1,007	50
Invasiveness, Neoplasm [description not available]	6.79	32	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	19.81	650	28
Liver Neoplasms Tumors or cancer of the LIVER.	22.06	1,007	50
Cirrhosis, Liver [description not available]	14.13	176	5
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	14.13	176	5
Colorectal Cancer [description not available]	13.26	82	5
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	13.26	82	5
Complication, Postoperative [description not available]	6.01	23	0
Hepatic Failure [description not available]	6.62	16	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	6.01	23	0
Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)	6.62	16	0
Cruveilhier-Baumgarten Syndrome Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.	3.41	5	0
Hypertension, Portal Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.	3.41	5	0
Lymphoma of Mucosa-Associated Lymphoid Tissue [description not available]	2.6	1	0
Lymphoma, B-Cell, Marginal Zone Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.	2.6	1	0
Chronic Liver Failure [description not available]	5.69	17	1
End Stage Liver Disease Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.	5.69	17	1
Chronic Hepatitis C [description not available]	3.98	11	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	19.56	500	34
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	3.98	11	0
Chronic Hepatitis B [description not available]	4.03	11	0
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	4.03	11	0
Coagulation, Disseminated Intravascular [description not available]	2.41	1	0
Thrombopenia [description not available]	2.41	1	0
Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.	2.41	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.41	1	0
Biliary Tract Cancer [description not available]	3.46	2	0
Biliary Tract Neoplasms Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.	3.46	2	0
Besnier-Boeck Disease [description not available]	2.58	2	0
Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.	2.58	2	0
Cancer of Pancreas [description not available]	7.09	31	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	2.63	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	7.09	31	0
Adenocarcinoma, Basal Cell [description not available]	5.34	7	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	5.34	7	0
Bile Duct Cancer [description not available]	9.24	52	1
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	9.24	52	1
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	6.57	16	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	4.65	9	0
Tachypnea Increased RESPIRATORY RATE.	4.02	2	1
Cholangiocellular Carcinoma [description not available]	9.15	48	1
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	9.15	48	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	3.24	5	0
Acute-On-Chronic Liver Failure (ACLF) [description not available]	2.41	1	0
Acute-On-Chronic Liver Failure Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.	2.41	1	0
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	6.16	14	2
Bilirubinemia [description not available]	2.66	2	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	6.16	14	2
Ascites Accumulation or retention of free fluid within the peritoneal cavity.	2.63	2	0
Angioma, Cavernous A tumor-like mass with large vascular space that is filled with blood or lymph.	2.66	2	0
Airflow Obstruction, Chronic [description not available]	2.41	1	0
Hepatitis B Virus Infection [description not available]	3.41	6	0
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	3.41	6	0
Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.	3.12	4	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	2.41	1	0
Liver Dysfunction [description not available]	15.18	179	10
Liver Diseases Pathological processes of the LIVER.	15.18	179	10
Cyst [description not available]	5.07	9	0
Injuries, Radiation [description not available]	4.89	7	1
Adenoma, Hepatocellular [description not available]	9.48	43	2
Focal Nodular Hyperplasia Solitary or multiple benign hepatic vascular tumors, usually occurring in women of 20-50 years of age. The nodule, poorly encapsulated, consists of a central stellate fibrous scar and normal liver elements such as HEPATOCYTES, small BILE DUCTS, and KUPFFER CELLS among the intervening fibrous septa. The pale colored central scar represents large blood vessels with hyperplastic fibromuscular layer and narrowing lumen.	9.92	59	2
Inflammatory Pseudotumor [description not available]	2.87	3	0
Dendritic Cell Sarcoma, Follicular Sarcoma of FOLLICULAR DENDRITIC CELLS most often found in the lymph nodes. This rare neoplasm occurs predominately in adults.	2.41	1	0
Granuloma, Plasma Cell A slow-growing benign pseudotumor in which plasma cells greatly outnumber the inflammatory cells.	2.87	3	0
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	3.01	2	0
Innate Inflammatory Response [description not available]	4.63	8	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	4.63	8	0
Local Neoplasm Recurrence [description not available]	8.41	48	0
Acute Liver Injury, Drug-Induced [description not available]	6.58	6	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	6.58	6	1
Diabetes Mellitus, Adult-Onset [description not available]	2.82	2	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.82	2	0
Adenoma, Basal Cell [description not available]	3.8	10	0
Adenoma A benign epithelial tumor with a glandular organization.	3.8	10	0
Adolescent Obesity [description not available]	2.6	1	0
Fatty Liver, Nonalcoholic [description not available]	4	12	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	4	12	0
Digestive System Disorders [description not available]	2.57	2	0
Gall Bladder Diseases [description not available]	2.6	1	0
Digestive System Diseases Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).	2.57	2	0
Biliary Tract Diseases Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.	8.88	21	2
Blood Clot [description not available]	2.6	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.6	1	0
Cirrhosis [description not available]	4.41	7	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	4.41	7	0
Constriction, Pathological [description not available]	3.98	4	0
Cholangiitis, Sclerosing [description not available]	3.84	10	0
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	3.98	4	0
Cholangitis, Sclerosing Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.	3.84	10	0
Disease Exacerbation [description not available]	6.82	34	0
Canine Diseases [description not available]	3.95	2	1
Respiration Disorders Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.	2.21	1	0
Liver Steatosis [description not available]	7.86	25	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	7.86	25	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.54	22	0
Chronic Illness [description not available]	7.02	26	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	7.02	26	1
Cardiac Diseases [description not available]	2.21	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.21	1	0
Cicatrization The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.	2.93	3	0
Cicatrix The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.	2.93	3	0
Benign Neoplasms [description not available]	4.13	5	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.25	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.13	5	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	3.17	1	0
Allergy, Drug [description not available]	3.77	3	0
Atopic Hypersensitivity [description not available]	3.17	1	0
Nephrogenic Systemic Fibrosis [description not available]	9.33	10	1
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	3.77	3	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	3.17	1	0
Nephrogenic Fibrosing Dermopathy A chronic, acquired, idiopathic, progressive eruption of the skin that occurs in the context of RENAL FAILURE. It is sometimes accompanied by systemic fibrosis. The pathogenesis seems to be multifactorial, with postulated involvement of circulating fibrocytes. There is a strong association between this disorder and the use of gadolinium-based contrast agents.	9.33	10	1
Metastase [description not available]	9.87	18	2
Hepatic Veno Occlusive Disease [description not available]	3.4	6	0
Hepatic Veno-Occlusive Disease Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.	3.4	6	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	9.87	18	2
Cancer of Intestines [description not available]	2.61	2	0
Cancer of Stomach [description not available]	4.24	3	1
Intestinal Neoplasms Tumors or cancer of the INTESTINES.	2.61	2	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	4.24	3	1
Deep Vein Thrombosis [description not available]	2.58	2	0
Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein.	2.58	2	0
Chemical and Drug Induced Liver Injury, Chronic Liver disease lasting six months or more, caused by an adverse effect of a drug or chemical. The adverse effect may be caused by drugs, drug metabolites, chemicals from the environment, or an idiosyncratic response.	2.72	2	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	5.27	6	2
Angioma, Sclerosing [description not available]	2.31	1	0
Histiocytoma, Benign Fibrous A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)	2.31	1	0
Angiogenesis, Pathologic [description not available]	9.53	34	2
Hemangioendothelioma, Epithelioid A tumor of medium-to-large veins, composed of plump-to-spindled endothelial cells that bulge into vascular spaces in a tombstone-like fashion. These tumors are thought to have borderline aggression, where one-third develop local recurrences, but only rarely metastasize. It is unclear whether the epithelioid hemangioendothelioma is truly neoplastic or an exuberant tissue reaction, nor is it clear if this is equivalent to Kimura's disease (see ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA). (Segen, Dictionary of Modern Medicine, 1992)	3.07	4	0
Cancer of Prostate [description not available]	3.7	1	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.7	1	1
Pancreatic Fistula Abnormal passage communicating with the PANCREAS.	2.31	1	0
Viral Hepatitis, Human [description not available]	2.55	2	0
Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).	2.55	2	0
Chronic Kidney Failure [description not available]	2.53	2	0
Gradenigo Syndrome Inflammation of PETROUS BONE secondary to chronic OTITIS MEDIA. Its symptoms include fever, occipital headache, ear and retroorbital pain, and facial paralysis.	2.31	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	2.53	2	0
Angioma A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.	8.93	31	2
Hemangioma A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)	8.93	31	2
Bile Duct Obstruction [description not available]	3.54	8	0
Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).	3.54	8	0
Angiomyolipoma A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)	5.34	8	0
Disease, Pulmonary [description not available]	3.48	2	0
Lung Diseases Pathological processes involving any part of the LUNG.	3.48	2	0
Condition, Preneoplastic [description not available]	4.65	9	0
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	4.65	9	0
Angiosarcoma [description not available]	2.57	2	0
Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)	2.57	2	0
Impaired Glucose Tolerance [description not available]	2.17	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.17	1	0
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.17	1	0
Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)	3.02	4	0
Experimental Hepatoma [description not available]	3.41	7	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.78	3	0
Hepatic Insufficiency Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.	3.56	1	1
Germinoblastoma [description not available]	2.17	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.17	1	0
Cancer of Colon [description not available]	3.46	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	3.46	2	0
Injury, Ischemia-Reperfusion [description not available]	3.63	3	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	3.63	3	0
Cancer, Second Primary [description not available]	3.03	4	0
Cystic Fibrosis of Pancreas [description not available]	2.21	1	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	2.21	1	0
Degenerative Disc Disease [description not available]	2.21	1	0
Low Back Ache [description not available]	2.21	1	0
Low Back Pain Acute or chronic pain in the lumbar or sacral regions, which may be associated with musculo-ligamentous SPRAINS AND STRAINS; INTERVERTEBRAL DISK DISPLACEMENT; and other conditions.	2.21	1	0
Intervertebral Disc Degeneration Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.	2.21	1	0
Blunt Injuries [description not available]	2.17	1	0
Bleeding [description not available]	3.12	1	0
Hemorrhage Bleeding or escape of blood from a vessel.	3.12	1	0
Iron Overload An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)	3.12	1	0
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	2.21	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.21	1	0
Cancer of Pelvis [description not available]	2.21	1	0
Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN.	2.53	2	0
Breast Cancer [description not available]	4.14	5	0
Breast Neoplasms Tumors or cancer of the human BREAST.	4.14	5	0
Alveolar Echinococcosis, Hepatic [description not available]	2.8	3	0
Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.	2.21	1	0
Recrudescence [description not available]	2.21	1	0
Alcoholic Cirrhosis [description not available]	2.52	2	0
Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.	2.52	2	0
Cancer of Rectum [description not available]	2.78	3	0
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.78	3	0
Abscess, Hepatic [description not available]	2.49	2	0
Liver Abscess Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.	2.49	2	0
Bile Duct Diseases Diseases in any part of the ductal system of the BILIARY TRACT from the smallest BILE CANALICULI to the largest COMMON BILE DUCT.	6.85	10	1
Empyema, Gall Bladder [description not available]	2.52	2	0
Cancer of Gallbladder [description not available]	2.49	2	0
Granulomas [description not available]	2.08	1	0
Xanthoma [description not available]	2.08	1	0
Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.	2.52	2	0
Gallbladder Neoplasms Tumors or cancer of the gallbladder.	2.49	2	0
Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.	2.08	1	0
Colicky Pain [description not available]	2.08	1	0
Multiple Primary Neoplasms [description not available]	3.03	4	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	2.08	1	0
Anastomotic Leak Breakdown of the connection and subsequent leakage of effluent (fluids, secretions, air) from a SURGICAL ANASTOMOSIS of the digestive, respiratory, genitourinary, and cardiovascular systems. Most common leakages are from the breakdown of suture lines in gastrointestinal or bowel anastomosis.	5.87	4	2
Gallstone Disease [description not available]	3	1	0
Cholelithiasis Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).	3	1	0
Aberrant Tissue [description not available]	2.08	1	0
Cholera Infantum [description not available]	2.08	1	0
Cancer of Gastrointestinal Tract [description not available]	3.01	4	0
Duodenal Diseases Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).	2.08	1	0
Enlarged Liver [description not available]	2.1	1	0
Atresia, Biliary [description not available]	3.43	2	0
Biliary Atresia Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.	3.43	2	0
Malignant Melanoma [description not available]	3.82	2	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	3.82	2	1
Uveal Neoplasms Tumors or cancer of the UVEA.	2.1	1	0
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	2.1	1	0
Chronic Hepatitis [description not available]	4.26	6	0
Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.	4.26	6	0
Minimal Disease, Residual [description not available]	3.04	4	0
Gastrointestinal Stromal Neoplasm [description not available]	2.51	2	0
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	2.51	2	0
Carcinosarcoma A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)	2.52	2	0
Cancer of Spleen [description not available]	2.1	1	0
Carcinoma, Ductal, Pancreatic [description not available]	4.13	5	0
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	4.13	5	0
Acute Cholecystitis [description not available]	3.88	2	1
Cholecystitis, Acute Acute inflammation of the GALLBLADDER wall. It is characterized by the presence of ABDOMINAL PAIN; FEVER; and LEUKOCYTOSIS. Gallstone obstruction of the CYSTIC DUCT is present in approximately 90% of the cases.	3.88	2	1
Hepatitis INFLAMMATION of the LIVER.	3.15	5	0
Splenic Diseases Diseases involving the SPLEEN.	2.1	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	2.1	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	2.1	1	0
Acute Necrotizing Pancreatitis [description not available]	2.1	1	0
Infarct [description not available]	2.1	1	0
Budd-Chiari Syndrome A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.	2.99	4	0
Carcinoma, Colloid [description not available]	2.79	3	0
Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)	2.79	3	0
Pancreatic Cyst A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)	2.11	1	0
Adenocarcinoma Of Kidney [description not available]	3.4	2	0
Cancer of Kidney [description not available]	3.4	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	3.4	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	3.4	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.78	3	0
Carbon Tetrachloride Poisoning Poisoning that results from ingestion, injection, inhalation, or skin absorption of CARBON TETRACHLORIDE.	3.35	2	0
Icterus [description not available]	2.11	1	0
Jaundice A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.	2.11	1	0
Breathlessness [description not available]	5.16	5	2
Dyspnea Difficult or labored breathing.	5.16	5	2
Dilatation, Pathologic The condition of an anatomical structure's being dilated beyond normal dimensions.	2.11	1	0
Sclerosis A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.	3.03	1	0
Adverse Drug Event [description not available]	3.51	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.51	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	3.51	1	1
Hyperplasia, Reactive Lymphoid [description not available]	2.78	3	0
Cholangioma [description not available]	2.5	2	0
Adenoma, Bile Duct A benign tumor of the intrahepatic bile ducts.	2.5	2	0
Neoplasms, Cystic, Mucinous, and Serous Neoplasms containing cyst-like formations or producing mucin or serum.	2.11	1	0
Carcinoma, Anaplastic [description not available]	6.07	10	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	6.07	10	1
Spinal Neoplasms New abnormal growth of tissue in the SPINE.	2.13	1	0
Esophageal Varices [description not available]	2.54	2	0
Esophageal and Gastric Varices Dilated blood vessels in the ESOPHAGUS or GASTRIC FUNDUS that shunt blood from the portal circulation (PORTAL SYSTEM) to the systemic venous circulation. Often they are observed in individuals with portal hypertension (HYPERTENSION, PORTAL).	2.54	2	0
Acute Kidney Failure [description not available]	2.11	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	2.11	1	0
Lipidoses Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.	2.13	1	0
Biliary Fistula Abnormal passage in any organ of the biliary tract or between biliary organs and other organs.	2.13	1	0
Bile Duct Cysts [description not available]	2.13	1	0
Caroli Disease Congenital cystic dilatation of the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC). It consists of 2 types: simple Caroli disease is characterized by bile duct dilatation (ectasia) alone; and complex Caroli disease is characterized by bile duct dilatation with extensive hepatic fibrosis and portal hypertension (HYPERTENSION, PORTAL). Benign renal tubular ectasia is associated with both types of Caroli disease.	2.13	1	0
Peliosis Hepatis A vascular disease of the LIVER characterized by the occurrence of multiple blood-filled CYSTS or cavities. The cysts are lined with ENDOTHELIAL CELLS; the cavities lined with hepatic parenchymal cells (HEPATOCYTES). Peliosis hepatis has been associated with use of anabolic steroids (ANABOLIC AGENTS) and certain drugs.	2.13	1	0
Autoimmune Disease [description not available]	2.13	1	0
Acute Edematous Pancreatitis [description not available]	2.13	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	2.13	1	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2.13	1	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.13	1	0
Tuberculosis, Hepatic Infection of the LIVER with species of MYCOBACTERIUM, most often MYCOBACTERIUM TUBERCULOSIS. It is characterized by localized small tuberculous miliary lesions or tumor-like mass (TUBERCULOMA), and abnormalities in liver function tests.	2.13	1	0
Extravasation of Contrast Media [description not available]	2.13	1	0
Cirrhoses, Experimental Liver [description not available]	3.43	7	0
Sarcoma, Epithelioid [description not available]	2.15	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	2.15	1	0
Acid beta-Glucosidase Deficiency [description not available]	2.15	1	0
Gaucher Disease An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.	2.15	1	0
Neurilemoma [description not available]	2.52	2	0
Neurilemmoma A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)	2.52	2	0
Alcohol Abuse [description not available]	2.97	1	0
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	2.97	1	0
Diseases, Peripheral Vascular [description not available]	2.05	1	0
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	2.05	1	0
Cancer of Lung [description not available]	2.05	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.05	1	0
Apoplexy [description not available]	2.97	1	0
Benign Neoplasms, Brain [description not available]	2.97	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.97	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.97	1	0
Cystadenoma A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)	2.44	2	0
Pancreatic Diseases Pathological processes of the PANCREAS.	2.05	1	0
Eosinophilia, Tropical [description not available]	2.46	2	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	2.46	2	0
Biliary Cirrhosis [description not available]	2.05	1	0
Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.	2.05	1	0
Cancer of Cervix [description not available]	2.06	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.06	1	0
Acute Hepatic Failure [description not available]	2.06	1	0
Liver Failure, Acute A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.	2.06	1	0
Anasarca [description not available]	2.06	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.06	1	0
Alcoholic Fatty Liver [description not available]	2.06	1	0
Neoplasms, Vascular [description not available]	2.06	1	0
Deficiency, Glucosephosphatase [description not available]	2.07	1	0
Glycogen Storage Disease Type I An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.	2.07	1	0
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2.06	1	0
Cancer of Ovary [description not available]	2.06	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.06	1	0
Adrenal Cancer [description not available]	2.06	1	0
Arteriovenous Malformations Abnormal formation of blood vessels that shunt arterial blood directly into veins without passing through the CAPILLARIES. They usually are crooked, dilated, and with thick vessel walls. A common type is the congenital arteriovenous fistula. The lack of blood flow and oxygen in the capillaries can lead to tissue damage in the affected areas.	2.06	1	0
Neoplasm Metastasis, Unknown Primary [description not available]	2.06	1	0
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	2.06	1	0
Cancer of Head [description not available]	2.07	1	0
Lymph Node Metastasis [description not available]	2.45	2	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.07	1	0
Hepatoblastoma A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)	2.99	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.07	1	0
Lung Injury, Acute [description not available]	2.48	2	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.48	2	0
Acinar Carcinoma [description not available]	2.07	1	0
Carcinoma, Acinar Cell A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)	2.07	1	0
Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.	2.07	1	0
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	2.07	1	0
Back Ache [description not available]	2.07	1	0
Back Pain Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.	2.07	1	0
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	2.07	1	0
Common Bile Duct Neoplasms Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.	2.08	1	0
Bile Duct Obstruction, Intrahepatic [description not available]	1.98	1	0
Cholestasis, Intrahepatic Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).	1.98	1	0
Acute Disease Disease having a short and relatively severe course.	2.39	2	0
Common Bile Duct Diseases Diseases of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.	1.99	1	0
Hepatitis, Animal INFLAMMATION of the LIVER in non-human animals.	1.99	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.91	1	0
Experimental Radiation Injuries [description not available]	1.98	1	0

gadoxetic acid disodium

Description

Cross-References

Synonyms (9)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (1,597)

Study Types